IO Biotech, Inc. (IOBT)
NASDAQ: IOBT · Real-Time Price · USD
0.9600
+0.0372 (4.03%)
Apr 25, 2025, 4:00 PM EDT - Market closed

IO Biotech Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2019
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019
Selling, General & Admin
23.6923.6124.4411.081.68
Upgrade
Research & Development
71.4867.8346.9930.158.46
Upgrade
Operating Expenses
95.1891.4471.4241.2310.15
Upgrade
Operating Income
-95.18-91.44-71.42-41.23-10.15
Upgrade
Interest Expense
---0.3-0.36-0.03
Upgrade
Interest & Investment Income
4.725.881.41--
Upgrade
Currency Exchange Gain (Loss)
-3.590.330.130.320.11
Upgrade
EBT Excluding Unusual Items
-94.05-85.23-70.19-41.28-10.06
Upgrade
Other Unusual Items
----26.54-1.99
Upgrade
Pretax Income
-94.05-85.23-70.19-67.81-12.04
Upgrade
Income Tax Expense
1.440.851.270.07-
Upgrade
Net Income
-95.49-86.08-71.46-67.88-12.04
Upgrade
Preferred Dividends & Other Adjustments
---7.112.55
Upgrade
Net Income to Common
-95.49-86.08-71.46-74.99-14.59
Upgrade
Shares Outstanding (Basic)
66442940
Upgrade
Shares Outstanding (Diluted)
66442940
Upgrade
Shares Change (YoY)
51.31%51.10%564.62%2346.74%-
Upgrade
EPS (Basic)
-1.45-1.98-2.48-17.30-82.36
Upgrade
EPS (Diluted)
-1.45-1.98-2.48-17.30-82.36
Upgrade
Free Cash Flow
-82.39-72.06-60.42-40.8-9.96
Upgrade
Free Cash Flow Per Share
-1.25-1.66-2.10-9.41-56.19
Upgrade
EBITDA
-94.92-91.23-71.32-41.23-
Upgrade
D&A For EBITDA
0.250.220.10-
Upgrade
EBIT
-95.18-91.44-71.42-41.23-10.15
Upgrade
Updated Nov 12, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q